Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives
This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
1. A pharmaceutical composition comprising a compound of the formula:
wherein:
Y is alkanediyl (C≦8) , alkenediyl (C≦8) , alkynediyl (C≦8) , or a substituted version of any of these groups;
R a is:
hydrogen, hydroxy, halo, amino, nitro, cyano, azido, phosphate, 1,3-dioxoisoindolin-2-yl, mercapto or silyl; or
alkyl (C≦12) , alkenyl (C≦12) , alkynyl (C≦12) , aryl (C≦12) , aralkyl (C≦12) , heteroaryl (C≦12) , heteroaralkyl (C≦12) , acyl (C≦12) , alkoxy (C≦12) , alkenyloxy (C≦12) , alkynyloxy (C≦12) , aryloxy (C≦12) , aralkoxy (C≦12) , heteroaryloxy (C≦12) , heteroaralkoxy (C≦12) , acyloxy (C≦12) , alkylamino (C≦12) , dialkylamino (C≦12) , alkenylamino (C≦12) , alkynylamino (C≦12) , arylamino (C≦12) , aralkylamino (C≦12) , heteroarylamino (C≦12) , heteroaralkylamino (C≦12) , alkylsulfonylamino (C≦12) , amido (C≦12) , alkylthio (C≦12) , alkenylthio (C≦12) , alkynylthio (C≦12) , arylthio (C≦12) , aralkylthio (C≦12) , heteroarylthio (C≦12) , heteroaralkylthio (C≦12) , acylthio (C≦12) , thioacyl (C≦12) , alkylsulfonyl (C≦12) , alkenylsulfonyl (C≦12) , alkynylsulfonyl (C≦12) , arylsulfonyl (C≦12) , aralkylsulfonyl (C≦12) , heteroarylsulfonyl (C≦12) , heteroaralkylsulfonyl (C≦12) , alkylsulfinyl (C≦12) , alkenylsulfinyl (C≦12) , alkynylsulfinyl (C≦12) , arylsulfinyl (C≦12) , aralkylsulfinyl (C≦12) , heteroarylsulfinyl (C≦12) , heteroaralkylsulfinyl (C≦12) , alkylphosphonyl (C≦12) , alkylphosphate (C≦12) , dialkylphosphate (C≦12) , alkylammonium (C≦12) , alkylsulfonium (C≦12) , alkylsilyl (C≦12) , or a substituted version of any of these groups; or
Y and R a form a three to seven-membered ring, such that Y and R a are further connected to one another through one or more of —O— and alkanediyl (C1-5) , further wherein Y is —CH— and R a is —CH 2 —;
or a pharmaceutically acceptable salt or tautomer thereof; and
a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1 , wherein the compound is further defined as:
wherein R a is:
hydrogen, hydroxy, halo, amino, phosphate, 1,3-dioxoisoindolin-2-yl, or cyano; or
alkyl (C≦12) , alkenyl (C≦12) , alkynyl (C≦12) , aryl (C≦12) , aralkyl (C≦12) , heteroaryl (C≦12) , heteroaralkyl (C≦12) , acyl (C≦12) , alkoxy (C≦12) , alkenyloxy (C≦12) , alkynyloxy (C≦12) , aryloxy (C≦12) , aralkoxy (C≦12) , heteroaryloxy (C≦12) , heteroaralkoxy (C≦12) , acyloxy (C≦12) , alkylamino (C≦12) , dialkylamino (C≦12) , alkenylamino (C≦12) , alkynylamino (C≦12) , arylamino (C≦12) , aralkylamino (C≦12) , heteroarylamino (C≦12) , heteroaralkylamino (C≦12) , amido (C≦12) , arylsulfonyl (C≦12) , arylsulfinyl (C≦12) , alkylphosphate (C≦12) , dialkylphosphate (C≦12) , or a substituted version of any of these groups;
or pharmaceutically acceptable salt or tautomer thereof.
3. The pharmaceutical composition of claim 2 , wherein the compound is further defined as:
wherein R a is hydroxy, amino, acyl (C≦8) , substituted acyl (C≦8) , acyloxy (C≦8) , substituted acyloxy (C≦8) , amido (C≦8) , or substituted amido (C≦8) ;
or pharmaceutically acceptable salt or tautomer thereof.
4. The pharmaceutical composition of claim 1 , wherein Y is —C(OH)HCH 2 —.
5. The pharmaceutical composition of claim 3 , wherein R a is —OH.
6. The pharmaceutical composition of claim 1 , wherein R a is —Cl.
7. The pharmaceutical composition of claim 1 , wherein R a is —Br.
8. The pharmaceutical composition of claim 1 , wherein R a is —H.
9. The pharmaceutical composition of claim 1 , wherein R a is acyl (C1-3) or substituted acyl (C1-3) .
10. The pharmaceutical composition of claim 1 , wherein R a is acyloxy (C1-8) or substituted acyloxy (C1-3) .
11. The pharmaceutical composition of claim 1 , wherein R a is alkylamino (C≦12) , dialkylamino (C≦12) , alkenylamino (C≦12) , alkynylamino (C≦12) , arylamino (C≦12) , aralkylamino (C≦12) , heteroarylamino (C≦12) , heteroaralkylamino (C≦12) , alkylsulfonylamino (C≦12) , or amido (C≦12) , or a substituted version of any of these groups.
12. The pharmaceutical composition of claim 1 , wherein the compound is further defined as:
or a pharmaceutically acceptable salt or tautomer thereof.
13. The pharmaceutical composition of claim 1 , wherein the compound is further defined as:
or a pharmaceutically acceptable salt or tautomer thereof.
14. The pharmaceutical composition of claim 1 , wherein the compound is further defined as:
or a pharmaceutically acceptable salt or tautomer thereof.
15. The pharmaceutical composition of claim 1 , wherein the compound is further defined as:
or a pharmaceutically acceptable salt or tautomer thereof.
16. The pharmaceutical composition of claim 1 , wherein the compound is further defined as:
17. The pharmaceutical composition of claim 1 , wherein the compound is further defined as:
or a pharmaceutically acceptable salt or tautomer thereof.
18. The pharmaceutical composition of claim 1 , wherein the compound is further defined as:
or a pharmaceutically acceptable salt or tautomer thereof.
19. The pharmaceutical composition of claim 1 , wherein the compound is further defined as:
or a pharmaceutically acceptable salt or tautomer thereof.
20. The pharmaceutical composition of claim 1 , wherein the compound is further defined as:
or a pharmaceutically acceptable salt or tautomer thereof.
21. The pharmaceutical composition of claim 1 , wherein the compound is further defined as:
or a pharmaceutically acceptable salt or tautomer thereof.
22. The pharmaceutical composition of claim 1 , wherein the compound is further defined as:
or a pharmaceutically acceptable salt or tautomer thereof.
23. The pharmaceutical composition of claim 1 , wherein the compound is further defined as:
or a pharmaceutically acceptable salt or tautomer thereof.
24. The pharmaceutical composition of claim 1 , wherein the compound is further defined as:
or a pharmaceutically acceptable salt or tautomer thereof.
25. The pharmaceutical composition of claim 1 , wherein the compound is further defined as:
or a pharmaceutically acceptable salt or tautomer thereof.
26. The pharmaceutical composition of claim 1 , wherein the compound is further defined as:
or a pharmaceutically acceptable salt or tautomer of any of these formulas.
27. The pharmaceutical composition of claim 1 , wherein the composition is formulated for oral delivery.
28. A pharmaceutical composition comprising a compound of the formula:
and
a pharmaceutically acceptable carrier.